News Roche and Novartis colluded over wet AMD drugs, says Italian regulator BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2006 (Published 10 March 2014) Cite this as: BMJ 2014;348:g2006 Article Related content Metrics Responses Peer review Related articles News Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds Published: 23 July 2013; BMJ 347 doi:10.1136/bmj.f4678 News In brief Published: 17 June 2014; BMJ 348 doi:10.1136/bmj.g4075 Feature Attacks on publicly funded trials: what happens when industry does not want to know the answer Published: 01 April 2015; BMJ 350 doi:10.1136/bmj.h1701 See more Individual care plans reduce falls and broken hips in New Zealand hospitals BMJ December 05, 2016, 355 i6490; DOI: https://doi.org/10.1136/bmj.i6490 Bill to boost medical research funding and speed drug approval passes US house BMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498 Workloads threaten to undermine doctors’ training, GMC finds BMJ December 01, 2016, 355 i6495; DOI: https://doi.org/10.1136/bmj.i6495 Junior doctors’ low morale is putting patients at risk, Royal College of Physicians warns BMJ December 01, 2016, 355 i6493; DOI: https://doi.org/10.1136/bmj.i6493 Funds are not reaching frontline services BMJ November 28, 2016, 355 i6273; DOI: https://doi.org/10.1136/bmj.i6273 Cited by... Attacks on publicly funded trials: what happens when industry does not want to know the answerFulltext PDF In briefFulltext PDF